JCA Pulse › Ongoing JCA
Ongoing JCARelacorilant (Lifyorli): EU joint clinical assessment
Treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Regulatory review
- CHMP opinion
- EU authorised
- JCA report published
Overview
- Company
- Corcept Therapeutics
- Therapy area
- Solid tumours · Gynaecological
- Indication
- Treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Product type
- Chemical, Orphan designation
- EMA validation
- 30 Oct 2025
- JCA assessor
- INFARMED, Portugal
- Co-assessor
- SBU, Sweden
- Regulatory status
- CHMP positive 18 Sep 2026 (with nab-paclitaxel, 1–3 prior regimens). EC decision pending at 10 Nov 2026.
- Latest
- Awaiting EU authorisation; national HTA not started.
- Pivotal evidence
- ROSELLA (phase 3) + phase 2 (RCT)
Scope
The PICO forecast
JCA Pulse forecasts 3–5 PICOs across 2–3 populations for Relacorilant, with 6 candidate comparators. See the populations, comparators and likely outcomes the assessment is set to cover. Revised on 10 November 2026 against the five published JCA reports.
Evidence
Fit against the likely scope
Relacorilant’s pivotal evidence (ROSELLA) is randomised. Pro scores how well it fits each likely PICO and flags where assessors may push back.
Comparisons
Trials and indirect comparisons
Pro maps every trial likely in the Relacorilant dossier and projects the indirect comparison each comparator will need.
Countries
National translator and outlook
Portugal and Sweden lead the joint assessment. Pro explains what the JCA means for the national route in each of 31 markets.
Next milestones
- 18 Sep 2026CHMP positive opinion · EU · source
Sources
Last checked 10 November 2026. Compiled from public sources; check them for the latest position. Forecasts are Evidaxia’s independent view, not official assessments.
From Evidaxia
- EU JCA dossiers and PICO scopingSupport from PICO scoping to the dossier
- JCA PICO scoping: process and preparationHow assessors set the scope
- EU JCA timelineEvery upcoming milestone
Also in Solid tumours
- Bifikafusp alfa / onfekafusp alfa (Nidlegy)Melanoma, neoadjuvant
- CamizestrantHR+/HER2− breast cancer, ESR1 switch
- CosibelimabCutaneous squamous cell carcinoma
- DaraxonrasibMetastatic pancreatic cancer
- Ensartinib (Gevalka)ALK-positive NSCLC
- FuzuloparibmCRPC, first line